Sunitinib is an FDA-approved anti-cancer drug that blocks the autophosphorylation activity of IRE1α in a dose-dependent manner and, as a type I pharmacophore, is regarded as a potent activator of IRE1 RNase activity. This evidence concerns the gene ERN1 and cancer.